Title
Trends in antibiotic use and nosocomial pathogens in hospitalized veterans with pneumonia at 128 medical centers, 2006-2010

Permalink
https://escholarship.org/uc/item/23q8j6gp

Journal
Clinical Infectious Diseases, 61(9)

ISSN
1058-4838

Authors
Jones, BE
Jones, MM
Huttner, B
et al.

Publication Date
2015-11-01

DOI
10.1093/cid/civ629

Peer reviewed
TITLE: Trends in Antibiotic Use and Nosocomial Pathogens in Hospitalized Veterans with Pneumonia at 128 Medical Centers, 2006-2010.

AUTHORS:
Corresponding Author:
Barbara E Jones, MD, MSc
Division of Pulmonary & Critical Care Medicine. SLC VA Health System and University of Utah
Barbara.jones@hsc.utah.edu
30N 1900 E 701 Wintrobe
Salt Lake City, UT 84132
406-581-1930

Makoto Jones, MD, MSc. Division of Epidemiology and Infectious Disease, Salt Lake City VA Health System and University of Utah.

Benedikt Huttner, MD, MS. Infection Control Program and Division of Infectious Diseases, Geneva University Hospital, Geneva Switzerland.

data management, analysis, study design,

Gregory Stoddard, MS. Division of Epidemiology, University of Utah.

Kevin Antoine Brown, PhD. SLC VA Health System.

Vanessa Stevens, PhD. Pharmacotherapy Outcomes Research Center, College of Pharmacy, University of Utah, and SLC VA Health System.

Tom Greene, PhD, Division of Epidemiology, University of Utah.

Brian Sauer, PhD. Division of Epidemiology, SLC VA Health System and University of Utah.

Karl Madaras-Kelly, PharmD, MPH. Boise VA Medical Center and Idaho State University College of Pharmacy.

Michael Rubin, MD, PhD. Division of Epidemiology, Salt Lake City VA Health System and University of Utah.

Matthew Bidwell Goetz, MD. Division of Infectious Disease, Veterans Affairs Greater Los Angeles Healthcare System and David Geffen School of Medicine at UCLA.

Matthew Samore, MD. Division of Epidemiology, Salt Lake City VA Health System and University of Utah.
ABSTRACT

Background: In 2005, pneumonia practice guidelines recommended broad-spectrum antibiotics for patients with risk factors for nosocomial pathogens. The impact of these recommendations on providers’ ability to match empiric treatment with nosocomial pathogens is unknown.

Methods: Among hospitalizations with a principal diagnosis of pneumonia at 128 VA medical centers from 2006 through 2010, we measured annual trends in antibiotic selection, initial blood or respiratory cultures positive for MRSA, Pseudomonas aeruginosa, and Acinetobacter species, and alignment between antibiotic coverage and culture results for MRSA and Pseudomonas aeruginosa by calculating annual sensitivity, specificity, and diagnostic odds ratio [DOR] from a 2x2 contingency table.

Results:
Of 95,511 hospitalizations for pneumonia, initial use of vancomycin increased from 16% in 2006 to 31% in 2010, and piperacillin-tazobactam increased from 16% to 27%, while there was a decrease in both ceftriaxone (39% to 33%) and azithromycin (39% to 36%) (p<0.001 for all). The proportion of culture-positive MRSA hospitalizations decreased (2.5% to 2.0%, p<0.001); no change was seen for Pseudomonas aeruginosa (1.9% to 2.0%, p=0.14) or Acinetobacter spp. (0.2% to 0.2%, p=0.17). For both MRSA and Pseudomonas aeruginosa, sensitivity increased (46% to 65% and 54% to 63%, p<0.001) and specificity decreased (85% to 69% and 76% to 68%, p<0.001), with no significant changes in DOR (4.6 to 4.1, p=0.57 and 3.7 to 3.2, p=0.95).

Conclusions:
Between 2006 and 2010, we found a substantial increase in the use of broad-spectrum antibiotics for pneumonia despite no increase in nosocomial pathogens. Providers’ ability to accurately match antibiotic coverage to nosocomial pathogens remains low.
BACKGROUND:

Pneumonia is the leading infectious cause of death in the United States and results in 1.1 million hospitalizations annually.(1,2) Optimal treatment of pneumonia involves selecting an empiric antibiotic regimen (prior to return of results of microbiological tests) that targets pathogens while avoiding drugs that extend the spectrum of coverage to include organisms not causing infection. In 2005, the Infectious Disease Society of America (IDSA) and American Thoracic Society (ATS) introduced the classification of healthcare-associated pneumonia (HCAP), recommending empiric coverage of methicillin-resistant *Staphylococcus aureus* (MRSA) and *Pseudomonas aeruginosa* in patients meeting criteria for recent prior healthcare exposure.(3) The 2007 update of the community-acquired pneumonia (CAP) guidelines further emphasized that patients with risk factors for HCAP should be treated with broad-spectrum antibiotics.(4) Efforts to improve pneumonia outcomes have reinforced this recommendation through dissemination of the practice guidelines, performance measures by Medicare, and public health initiatives.(5,6)

Since the introduction of the HCAP classification, concerns have been raised that the risk factors for HCAP put forth by the guidelines are been too broad, driving excessive antibiotic use rather than improving providers’ ability to identify patients truly at risk for nosocomial pathogens.(7) It is unknown how these recommendations have impacted providers’ ability to match empiric broad-spectrum antibiotic treatment to patients at risk for nosocomial pathogens.

The U.S. Veterans Affairs (VA) health system uses a comprehensive electronic health record, with standardized medication and culture data. This allows us to measure
temporal trends in initial antibiotic selection and microbiology at the patient level across a large health system. We previously measured antibiotic prescribing practices and associations between positive MRSA cultures and anti-MRSA treatment for infection-related hospitalizations.\textsuperscript{(8,9)} Using the same dataset, our aims of this study were to evaluate annual trends in initial antibiotic selection and nosocomial pathogen identification over a 5-year period across the entire VA medical system, and to examine trends in the match between initial antibiotics and culture results. We tested the hypothesis that in the years following the dissemination of the guidelines, the match between broad-spectrum antibiotic use and culture results would increase.

METHODS:

Setting

This study was performed with data collected from 152 VA Medical Centers (VAMCs), between January 1, 2006 through December 31, 2010.\textsuperscript{(10)} We included all facilities with $\geq 10$ operational acute care beds and complete electronic medication administration records. All data were accessed and analyzed using Veterans Informatics, and Computing Infrastructure (VINCI).\textsuperscript{(11)}

Subject Selection

During the study period, we selected all hospitalizations from patients $\geq 18$ years of age at acute medical, surgical, or neurological wards and intensive care units. We then included hospitalizations with a principal International Classification of Disease, 9\textsuperscript{th} Revision, Clinical Modification (ICD-9)\textsuperscript{(12)} code consistent with pneumonia (481-
similar to other studies. (13, 14) Hospitalizations with ICD-9 codes for viral pneumonia and influenza (480.0-480.9, 487.0-488.19) were excluded.

To evaluate whether diagnostic coding for pneumonia was consistent during the study period relative to other diseases, we also identified all hospitalizations with principal ICD-9 codes consistent with sepsis (038.0, 038.11, 038.12, 038.x, 995.91, 995.92, 785.52), skin and soft tissue infections (680, 681, 682, 683, 684, 685, 686), and genito-urinary infections (590, 595.0, 597, 598.0, 599.0, 614.0, 614.1, 614.2, 614.3, 614.4, 614.5, 616.0, 616.1, 616.3, 616.4).

**Measurements: Antibiotic Use**

Antibiotic use was measured using bar code medication administration (BCMA), which records all medications administered to hospitalized patients.(15) As we were interested in the use of antibiotics prior to culture results availability, initial antibiotic therapy was defined as the systemic administration of one or more doses of an antibiotic within the first 2 calendar days of hospitalization. We calculated the proportion of hospitalized patients receiving antibiotics for pneumonia. Respiratory fluoroquinolones were combined into a single category (moxifloxacin, levofloxacin, and gatifloxacin used in 2006), macrolides (azithromycin, clarithromycin and erythromycin), and tetracyclines (doxycycline and tetracycline). As multiple antibiotics may be administered concurrently and we desired to detect breadth of coverage for pneumonia pathogens, we then classified antibiotics with activity against the following pathogen types: atypical organisms (respiratory fluoroquinolone, macrolide, or tetracycline); standard organisms (guideline-concordant coverage with either an anti-pneumococcal, non-anti-pseudomonal beta-lactam listed in Figure 3 plus macrolide, or a respiratory fluoroquinolone); MRSA
(vancomycin or linezolid), and single coverage for *Pseudomonas aeruginosa* (piperacillin-tazobactam, ticarcillin-clavulanate, ceftazidime, cefepime, meropenem, doripenem, imipenem, aztreonam). Since guidelines call for combination therapy to ensure coverage of *Pseudomonas aeruginosa*, an additional category was created requiring the combination of single coverage with an anti-pseudomonal fluoroquinolone (ciprofloxacin or levofloxacin) or aminoglycoside, consistent with guideline recommendations (4).

**Measurements: Microbiology Data**

We accessed microbiology data on all cultures drawn at any time during each hospitalization, which were standardized into Systemized Nomenclature of Medicine (SNOMED-CT) format.(16) Organism data were included if susceptibility testing was performed. Initial positive cultures for three common nosocomial pathogens associated with pneumonia – MRSA, *Pseudomonas aeruginosa*, and *Acinetobacter spp.* – were identified. We classified culture source into blood, respiratory (sputum, endotracheal aspirate, bronchiolar lavage, wash, or biopsy, or pleural fluid) or “other,” which included wound and urine cultures. Since we were interested in identifying pathogens that were present upon hospital admission rather than acquired during a hospitalization, we defined a positive initial pneumonia-related culture as any positive result that had been drawn during the first 2 calendar days of the hospitalization, from either blood or respiratory sources.

**Statistical Analysis**
To assess providers’ ability to accurately differentiate patients at risk for nosocomial pathogens, we examined trends in the alignment between the selection of initial antibiotics and recovery of organisms from microbiologic cultures. Our assessment is thus similar to the evaluation of accuracy of a diagnostic test (Table). A “True positive” was defined as the match between initial treatment and positive growth of the targeted organism in culture. A “true negative” was defined as the absence of coverage for a pathogen and lack of recovery of the corresponding organism. For example, a MRSA “true positive” was a hospitalization in which initial anti-MRSA therapy was administered and a pneumonia-related culture was positive for MRSA, while a “true negative” occurred if no anti-MRSA therapy was administered and no MRSA-positive cultures were identified. Sensitivity (Se) represented the proportion of admissions with MRSA-positive cultures that received an anti-MRSA drug, and specificity (Sp) represented the proportion of admissions without positive MRSA cultures that did not receive anti-MRSA therapy.

The diagnostic odds ratio (DOR) was calculated as a composite measure of performance to reflect both sensitivity and specificity (17). The DOR equals the positive likelihood ratio divided by the negative likelihood ratio, or (Se*Sp)/([1-Se]*[1-Sp]) – see Table). The greater the DOR, the greater the overall sensitivity and specificity, and overall matching between culture and coverage, that occurred. For example, a sensitivity and specificity of 0.50 would result in a DOR of 1, while sensitivity and specificity of 0.75 would result in a DOR of 9. To measure trends in the coverage-culture concordance for MRSA or Pseudomonas aeruginosa, we calculated annual sensitivity, specificity, and the diagnostic odds ratio for each year, the difference in the proportion of all true positive
cases and false positive cases from 2006 to 2010, and the ratio of the number of additional false positives per additional true positives identified in 2010 compared to 2006.

Temporal trends in antibiotic use, nosocomial pathogens, and alignment between coverage and culture results were analyzed using logistic generalized estimating equation (GEE) models, which took facility-level correlations into consideration. Calendar year was added as the single independent variable. All statistical analyses were performed using STATA, Version 12.0 (StataCorp, College Station, TX) and R (http://cran.r-project.org).

The study was conducted with approval from the University of Utah Institutional Review Board and the Salt Lake City VA Human Research Protection Program.

RESULTS:

Temporal Trends: diagnosis and demographics

One hundred twenty-eight facilities met inclusion criteria. Of a total of 2.4 million hospitalizations during the study period, 95,511 (3.9%) had a principal diagnosis of pneumonia. The proportion of hospitalizations for pneumonia remained stable over time, in contrast to the increase seen in sepsis diagnoses (Figure 1). Of the pneumonia hospitalizations, median patient age was 71 (mean 70, interquartile range 61-81), and median length of stay was 4 days (mean 6 days, interquartile range 3-7). Twelve percent of all pneumonia hospitalizations were initially admitted to the intensive care unit (ICU).

Antibiotic use
Antibiotic use for Veterans hospitalized with pneumonia shifted significantly during the 5-year period (Figure 2). Initial use of vancomycin increased from 16% to 31% (p<0.001), and piperacillin-tazobactam increased from 16% to 27% (p<0.001), while ceftriaxone and azithromycin decreased (p<0.001). Macrolides, of which 99.5% were azithromycin, decreased from 39.5% to 36.0% (p<0.001). Overall, anti-pseudomonal coverage and MRSA therapy increased, and a significant decline in initial therapy with standard and atypical coverage was observed (Figure 3; p<0.001 for all). The proportion of hospitalizations with initial double anti-pseudomonal coverage, while low, also increased significantly during the study period (5% to 11%, p<0.001). The proportion of hospitalizations that did not receive any guideline-concordant antibiotics was 8.1%. The most common antibiotics used in these hospitalizations were ciprofloxacin (single therapy), clindamycin, and trimethoprim/sulfamethoxazole. We found a small, nonsignificant increase in hospitalizations with discordant therapy over the study period (7.7% in 2006 to 8.3% in 2010, p=0.055).

Microbiology and culture-coverage concordance

Overall, 84.5% of pneumonia hospitalizations had documentation of at least one culture obtained from a blood or respiratory specimen within 2 days of admission. Respiratory cultures were less frequently collected (34.0% of hospitalization) than blood cultures (81.7% of hospitalizations). We found a small increase in blood culture collection (79.7% in 2006 to 82.1% in 2010, p<0.001) and no significant change in proportion of hospitalizations with respiratory cultures obtained.

The overall proportion of hospitalizations with positive initial cultures was 2.2% for MRSA, 2.0% for Pseudomonas aeruginosa, and 0.2% for Acinetobacter spp. A
significant decline in MRSA was observed, while *Pseudomonas aeruginosa* and *Acinetobacter spp.* remained stable (Figure 4). Of the positive cultures, 88% of MRSA, 96% of *Pseudomonas aeruginosa*, and 76% *Acinetobacter spp.*-positive cultures were from a respiratory source.

Figure 5 displays annual trends in sensitivity, specificity, and DORs for the alignment between antibiotic coverage and culture results for MRSA and *Pseudomonas aeruginosa*. For both pathogens, sensitivity increased and specificity decreased substantially. The resulting annual diagnostic odds ratios for both pathogens demonstrated no significant change from 2006 to 2010 (MRSA: 4.6 to 4.1, p=0.57; *Pseudomonas aeruginosa*: 3.1 to 2.8, p=0.95). The proportion of true positive cases for MRSA increased from 1.1% to 1.3%, while the proportion of false positive cases increased from 15.0% to 30.6%; for every single additional case positive for MRSA covered with anti-MRSA therapy by 2010, the additional number of negative-culture hospitalizations receiving coverage was 115. The proportion of true positive cases for *Pseudomonas aeruginosa* increased from 0.9% in 2006 to 1.2%, while the false positive cases increased from 21.0% to 33.6%; for every additional case of *Pseudomonas aeruginosa* treated with anti-pseudomonal coverage, the additional number of culture-negative hospitalizations receiving coverage was 42.

**DISCUSSION:**

Antibiotic selection for pneumonia is challenging, with consequences to both individual patients and the public health that are difficult to weigh. Because microbiologic tests are imperfect, whether or not a patient is given broad-spectrum
antibiotics depends upon a provider’s estimation of the probability of resistant pathogens as well as his/her threshold for treatment. When a causative pathogen is uncertain, as is the case for most patients with pneumonia, providers must perform the difficult task of weighing the risks and benefits of overtreatment versus under-treatment.

Our 5-year study of over 95,000 hospitalizations for pneumonia across the VA system is the first to examine trends in antibiotic use and culture results together on a large scale. We found a substantial shift toward broad-spectrum agents. During the same time period, we found no increase in initial cultures positive for the three most common nosocomial pathogens.

The shift in antibiotic use to broad-spectrum agents for pneumonia is not unique to the VA system. Berger et al reviewed nationwide antibiotic practices in the United States and found similar trends for hospitalized non-ICU pneumonia patients.(18) The decrease seen in MRSA pneumonia has also been suggested in other studies during the same time period,(19, 20, 21, 22), in contrast to the period of 2000-2005, in which there was a rise in diagnostic coding for MRSA (23). The prevalence of *Pseudomonas aeruginosa* among hospitalized patients with pneumonia has also been previously reported to be stable.(20, 22)

By combining antibiotic administration and culture data, our study examined whether the observed trends in antibiotic use observed resulted in a change in clinicians’ ability to match broad-spectrum antibiotic coverage to cultures for nosocomial pathogens. The increase in use of broad-spectrum antibiotics was comparable in patients with and without positive cultures, and the match between treatment and pathogen remained unchanged. These results suggest that the shift toward broad-spectrum antibiotics reflects
a change in criteria for decision-making rather than a response to increased prevalence or enhanced ability to identify patients at risk for resistant organisms. Increased recognition of HCAP risk factors, largely driven by dissemination of guidelines, likely modified clinicians’ perception of risk. This change was not accompanied by an improvement in discrimination of which patients actually have MRSA or *Pseudomonas aeruginosa* infection. While the increase in broad-spectrum antibiotics did result in an increase in coverage of more patients with nosocomial pathogens, this came at a cost of treating a large number of patients with broad-spectrum antibiotics unnecessarily.

Our study was not designed to determine whether the increase in vancomycin or piperacillin-tazobactam made a positive or negative impact on clinical outcomes. Patients meeting HCAP criteria demonstrate higher mortality risk and a higher risk of nosocomial pathogens, hence it was felt that this increase in mortality may be due to inadequate therapy. However, since the adoption of the HCAP definition, the studies examining clinical outcomes have found no improvement or an increase in mortality associated with the use of therapy with broad-spectrum antibiotics for this group. (24) However, since the adoption of the HCAP definition, the studies examining clinical outcomes have found no improvement or an increase in mortality associated with the use of therapy with broad-spectrum antibiotics for this group. (25, 26, 27, 28, 29), although one study suggested a possible benefit to broader-spectrum therapy when applying a more refined risk assessment. (31) As the proportion of patients receiving broad-spectrum antibiotics increased, those receiving standard therapies decreased, including coverage for atypical pneumonia pathogens. This raises concern that excessive use of broad-spectrum antibiotics could promote under-use of more standard therapies and failure to cover more common pneumonia pathogens.

Currently, clinicians have few tools to improve their ability to match antibiotics to likely pathogens for pneumonia. Refining and validating the clinical risk factors for
nosocomial pathogens has been a major recent focus of research, (32, 33) although accuracy in predicting resistant pathogens remains low for all risk prediction scores proposed. (33, 34) The development of new accurate rapid diagnostic tests as well as more consistent use of tests currently available may increase our yield of pathogens and include initial respiratory cultures (documented in only 32% of our patients, although the majority of positive cultures were identified from a respiratory source) and nasal MRSA surveillance testing (VA’s system-wide program has demonstrated high negative predictive value when compared to cultures for pneumonia patients) (9) In lieu of rapid identification and reliable clinical risk assessment, comparative effectiveness research evaluating the consequences of conservative versus aggressive antibiotic coverage strategies (ie, withholding broad-spectrum therapy until cultures result versus tailoring of antibiotics after cultures) will also improve our ability to base our empiric antibiotic selection on actual risks.

Study limitations include the use of administrative data that relied upon principal diagnostic codes to identify cases of pneumonia, and we did not attempt to identify patient-level clinical factors. It is thus possible that our results may have been affected by unmeasured changes in clinical population or diagnostic coding practices. Broadening the study population to include all principal diagnoses for pneumonia plus those with a secondary diagnosis for pneumonia with sepsis and respiratory failure as principal would have likely provided a slightly greater number of cases of severe pneumonia in the later years, and therefore may have resulted in a slightly higher proportion of hospitalizations with broad-spectrum antibiotic use and positive cultures. However, the profound rate of increase in both piperacillin-tazobactam and vancomycin suggests that providers have
decreased their threshold of use on similar patients. Our examination of whether
increases in broad-spectrum antibiotic use were associated with changes in the match
between antibiotic coverage and culture results should not be construed as an individual
measure of quality. We did not report trends in more typical community-acquired
pneumonia pathogens or less common resistant pathogens, such as those that carry
extended-spectrum beta-lactamases for which broad-spectrum antibiotics are indicated.
At the individual level, it is impossible to determine the appropriateness of broad-
spectrum antibiotic use for any given patient from our study. Rather, we aimed to develop
a population metric that is informative about thresholds for decision-making.

Clinicians continue to be challenged by the dilemma of whether to use broad-
spectrum antibiotics in the treatment of pneumonia. Unnecessary use of broad-spectrum
antibiotics carries substantial risk, both to the individual patient and to public health. So
does under-treatment of resistant pathogens. Given the raised awareness of antimicrobial
resistance brought forth by practice guidelines, it is not surprising that providers at the
VA, as in other systems, have lowered their threshold since their dissemination. Our study
suggests, however, that even with an increased caliber of the shotgun, we are still missing
the mark. Our study supports urgent need of research that examines the impact of this
change in threshold on outcomes and better strategies to identify patients who would
truly benefit from broad-spectrum antibiotics. Without better evidence that helps
providers weigh the risks and benefits of broad-spectrum antibiotic use for their
pneumonia patients, we are likely to see continued excessive use of this important
resource.
CONCLUSIONS:

We found a substantial increase in the use of both vancomycin and piperacillin-tazobactam from the years 2006 to 2010 in a national population of 95,511 hospitalized Veterans with pneumonia, with no increase in initial positive cultures for methicillin-resistant *Staph aureus*, *Pseudomonas aeruginosa*, or *Acinetobacter spp.* While providers’ threshold for broad-spectrum antibiotic use has decreased, the ability to accurately match antibiotic coverage to culture results for MRSA and *Pseudomonas aeruginosa* has not improved.

ACKNOWLEDGMENTS:

The authors would like to thank Pat Nechodom PhD and Saundra Duffy-Hawkins for administrative support and Kevin Nechodom PhD for guidance with data management. BE Jones was supported by a training grant from the National Institutes of Health (5 T32 – HL - 105321-1). The authors have no conflicts of interest to disclose. BE Jones had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Additional author contributions are: M Jones, management of the data and manuscript preparation and review; B. Huttner, collection and management of the data and manuscript preparation and review; G. Stoddard, design of the study and analysis of the data and preparation and review of the manuscript; T. Greene, design of the study and preparation and review of the manuscript; B. Sauer, preparation and review of the manuscript; K. Madars-Kelly, study design and preparation and review of the manuscript; M. Rubin, collection and
management of the data and review and approval of the manuscript; M. Samore, design
of the study and review and approval of the manuscript.

The views expressed in this article are those of the authors and do not necessarily
reflect the position or policy of the Department of Veterans Affairs or the United States
government.
REFERENCES: